Predicting breast cancer recurrence after extended hormone therapy
Treatments studied
Part of Cancer, Skin clinical trials.
This trial looks at factors that may predict whether hormone receptor–positive breast cancer will come back after you’ve already completed 5 years of hormone (endocrine) therapy. It may help identify who benefits most from longer treatment and follow-up.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early-stage invasive breast cancer that is estrogen-receptor and/or progesterone-receptor positive
- You finished the usual 5 years of hormone therapy and had no recurrence or spread to other sites (metastasis)
- You are 18 to 70 years old
- You must have at least one high-risk feature: fast-growing marker (Ki-67 ≥ 30%), tumor bigger than 2 cm, cancer in lymph nodes, grade 3 tumor, cancer clot in a blood vessel, or HER2 gene overexpression/amplification
- You have never had another different cancer before, and you haven’t joined another clinical trial recently
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if taking hormone therapy for 5 more years helps prevent breast cancer from coming back. It is for women who have already completed 5 years of tamoxifen or an aromatase inhibitor and had lymph node involvement at diagnosis.
This trial checks whether specific “surveillance” markers (measured from blood and bone marrow) can help predict if breast cancer comes back after standard treatments. It may help doctors monitor you more accurately and earlier if recurrence risk is high.
This trial is testing how well a short course of hormone-blocking pills (endocrine therapy) works before surgery in women with early-stage hormone receptor-positive HER2-negative breast cancer. The goal is to understand what makes some cancers resistant to these treatments.
This trial looks at how certain proteins (ER, PR, and HER2/neu) on breast cancer cells change when the cancer comes back in the same spot. Knowing this could help doctors choose the best treatment for your recurrence.
This study looks at the potential harms and benefits of hormone (endocrine) therapy in people age 70 and older with early-stage, hormone-receptor–positive breast cancer. It may help doctors choose which hormone treatment approach is safest and most helpful for older patients.
This study looks at how genetic tests like Oncotype DX or Mammaprint are used to guide treatment decisions for people with early-stage, hormone receptor-positive (HR+) and HER2-negative breast cancer. It aims to help doctors choose between hormone therapy alone or chemotherapy plus hormone therapy.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.